CEFALY Showcases Innovative Migraine Treatment Device at ACOG Annual Meeting

CEFALY Technology at the ACOG Annual Meeting



CEFALY Technology, a pioneering medical device manufacturer, is gearing up to introduce its groundbreaking neuromodulation device, designed specifically for migraine treatment, at the upcoming Annual Clinical and Scientific Meeting of the American College of Obstetricians and Gynecologists (ACOG) happening from May 16 to 18, 2025, in Minneapolis, Minnesota.

The event is a significant gathering for professionals in the field, boasting over 60,000 members affiliated with obstetrics and gynecology. It stands as the largest occasion in the United States dedicated to advancements in obstetric and gynecological health. CEO Jen Trainor-McDermott expressed her enthusiasm, stating, “Migraine poses a complex challenge and often debilitating neurological disorder that affects one in five women. We are excited to demonstrate CEFALY as a safe, effective, and drug-free alternative for patients.”

Migraine is particularly prevalent among women during their childbearing years, creating additional hurdles for those needing treatment during pregnancy. Many conventional medications, both acute and preventative, are often contraindicated during this time due to potential risks of birth defects or adverse effects on fetal development.

Indeed, a survey from the American Registry of Migraine Research indicated that nearly 20% of women experiencing migraines chose to avoid pregnancy. Concerns ranged from worsening migraine symptoms during pregnancy to the fear that migraine medications could adversely affect the child’s development.

As such, innovative solutions like CEFALY have gained traction. This non-invasive device, which is worn on the forehead, works by stimulating the trigeminal nerve, thereby relieving migraine pain and preventing future attacks. Many women have found success with CEFALY during pregnancy without any reported serious side effects. However, the FDA has yet to evaluate its efficacy and safety in pregnant women fully.

CEFALY is currently ongoing with an online registry aimed at collecting valuable information about non-pharmaceutical migraine relief options for expectant mothers. Michael A. L. Johnson, MD, serving as the Medical Affairs Advisor, will be on hand to discuss this important research initiative and answer queries related to the clinical applicability of the CEFALY device.

Attendees at the ACOG event will have the unique opportunity to experience the CEFALY Connected device firsthand, feeling the gentle neurostimulation that has provided relief to many. Moreover, clinicians are encouraged to enroll in the CEFALY Certified education program, which illustrates the basis of external trigeminal nerve stimulation (eTNS) in migraine treatment.

As CEFALY Technology seeks to forge meaningful relationships with ACOG members, they remain dedicated to delivering a safe, non-pharmacological option for migraine treatment.

About CEFALY Technology
Based in Darien, Connecticut, and rooted in Belgium, CEFALY Technology produces the FDA-approved CEFALY device, which is clinically validated to alleviate migraine frequency and pain. Their mission centers on providing innovative, cutting-edge technologies that empower individuals with migraines to take control of their treatment and lead fulfilled, healthier lives. Additional information about CEFALY is available on their official website, CEFALY.com, as well as their social media platforms including Facebook, Twitter, LinkedIn, Instagram, and TikTok.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.